Qfitlia (fitusiran) injection 50mg/0.5ml logo
Connect With a Sanofi Educator
The image of a man playing with his dog inside a yellow circle connected to 5 other circles on a blue rectangular background
The image of a man playing with his dog inside a yellow circle connected to 5 other circles on a blue rectangular background

Bleed management guidance for Qfitlia™ (fitusiran)

Keep your bleed management plan handy

Qfitlia is a prophylactic treatment only

A paper with the corner folded inside a yellow circle background

Before starting Qfitlia, your doctor will create a bleed management plan with you, including lower/less frequent factor replacement or bypassing agent doses while on Qfitlia to reduce thrombosis risk.

Blood cells inside a yellow circle background

Qfitlia works differently, so using it with factor replacement or bypassing agents increases potential for excessive blood clotting, or thrombosis.

Outline of a doctor on a yellow circle background

The bleed management plan must be followed when undergoing surgery while on Qfitlia. People have undergone both major (N=60) and minor (N=71) surgeries without discontinuing Qfitlia prophylaxis in clinical studies.

It is critical to follow your bleed management plan should a breakthrough bleed occur during Qfitlia treatment.

Hemophilia emergency card

Download and fill out your hemophilia emergency card with essential details and your bleed management plan.

Download

Emergency phone guide

Download instructions for updating your phone's emergency details.

Download

How to inject Qfitlia

Your healthcare provider will teach you how to use Qfitlia. This video can give you an idea of what to expect.

Learn How

Learn more about creating your own bleed management plan

Download our easy-to-follow guide, packed with helpful tips and information.

Learn How
The image of a man, Nick, CoRe Manager, in a circle with a blue background and yellow outline

Find a Sanofi Educator and connect today

Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options.

The image of a man, Nick, CoRe Manager, in a circle with a blue background and yellow outline

Important Safety Information and Indication
INDICATION
IMPORTANT SAFETY INFORMATION
INDICATION
Qfitlia™ (fitusiran) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors.

It is not known if Qfitlia is safe and effective in children younger than 12 years of age.
IMPORTANT SAFETY INFORMATION

Qfitlia can cause SERIOUS SIDE EFFECTS, including:

  • Abnormal blood clotting (thrombotic events): Serious blood clots have occurred in people treated with Qfitlia. Qfitlia can cause blood clots to form in the blood vessels in your arms, legs, lungs, heart, brain, eyes, or head. Your risk of blood clots is greater if your antithrombin (AT) blood level is persistently less than 15% or if you have certain other conditions. Your healthcare provider (HCP) will check your AT blood levels before and during treatment with Qfitlia

  • Gallbladder disease: Qfitlia can cause gallstones and inflammation of your gallbladder, which might require surgery to remove your gallbladder. Tell your HCP right away if you develop stomach pain, indigestion, nausea, or vomiting. Your HCP may temporarily or permanently stop Qfitlia if you develop any of these symptoms


What is the most important information I should know about Qfitlia?

Qfitlia helps your blood form clots. Do not stop using Qfitlia without talking to your HCP. If you miss doses or stop using Qfitlia, you may no longer be protected against bleeding.


Use of a clotting factor concentrate (CFC) or bypassing agent (BPA) to help protect against bleeding must be stopped within 7 days after your first dose of Qfitlia.


Your HCP may prescribe on-demand CFC or BPA if you bleed during treatment with Qfitlia. Carefully follow your HCP’s instructions regarding when to use on-demand treatment with CFC or BPA, including the prescribed dose and timing of the CFC or BPA.


Get medical help right away if you get any of these signs or symptoms of blood clots during or after treatment with Qfitlia:

  • Swelling, pain, or redness in arms or legs
  • Coughing up blood
  • Shortness of breath
  • Severe chest pain or tightness of the chest
  • Fast heart rate
  • Feeling faint or passing out
  • Severe or persistent headache
  • Difficulty speaking or understanding language
  • Feeling confused
  • Numbness or weakness in your face, arms, or legs
  • Sudden loss or changes in your vision, eye pain, or swelling

What are the possible side effects of Qfitlia?

  • Qfitlia can cause other serious side effects, including an increase in your blood liver enzymes. Your HCP will do blood tests to check your liver function before and during treatment with Qfitlia

  • The most common side effects of Qfitlia include viral infection, common cold symptoms, and bacterial infection

These are not all the possible side effects of Qfitlia.


What should I tell my HCP before using Qfitlia?

  • Tell your HCP about all of your medical conditions, including if you have liver problems, a history of gallbladder disease, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed

  • Females who are able to become pregnant: Hormonal birth control may increase your risk of blood clots if used during treatment with Qfitlia. Talk to your HCP about effective forms of non-hormonal birth control you can use before starting and during treatment with Qfitlia

  • Tell your HCP about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements

© 2025 Sanofi. All rights reserved. Qfitlia and Sanofi are trademarks of Sanofi or an affiliate. All other trademarks above are the property of their respective owners. Qfitlia is sold under license from Alnylam Pharmaceuticals, Inc. MAT-US-2413071-v1.0-03/2025 Last Updated: March 2025